Roche stopped work on emugrobart (GYM329) and returned the muscle-building obesity program to Chugai, ending a trial that tested the experimental medicine with an anti-obesity injectable. The decision marks a retreat from a development strategy aimed at addressing both weight reduction and muscle preservation. The termination also reflects the difficulty of proving added benefit beyond GLP-1–class efficacy, especially when balancing skeletal muscle outcomes and tolerability. The companies’ focus will likely shift to remaining metabolic programs and partnered assets with clearer risk-reward profiles.